Systemic inflammation also plays a central role in MASLD development, with cytokines, like tumor necrosis factor (TNF), shown to impair insulin signaling and to promote hepatic inflammation and fibrosis through the activation of hepatic stellate cells [8,11,12]. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.